AbCellera Biologics Inc.
Clinical trials sponsored by AbCellera Biologics Inc., explained in plain language.
A biotechnology company that discovers and develops antibody-based therapies using its AI-driven platform.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could cool menopause hot flashes Results expected Feb 2027 (estimated) May already have reported ↗
- New drug ABCL575 put to the test in healthy people Results expected Apr 2027 (estimated) May already have reported ↗
-
New shot could cool menopause hot flashes
Symptom relief OngoingThis early-stage trial tests a new biologic drug called ABCL635 for moderate-to-severe hot flashes in postmenopausal women. The study first checks safety in healthy volunteers, then measures how well the drug reduces hot flash frequency and severity. About 136 people will take pa…
Phase 1/2 • Sponsor: AbCellera Biologics Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug ABCL575 put to the test in healthy people
Knowledge-focused OngoingThis early-stage study tests the safety of a new drug called ABCL575 in 40 healthy adults. Participants receive either a single dose of the drug or a placebo. The goal is to check for side effects and how the body processes the drug, not to treat any disease.
Phase 1 • Sponsor: AbCellera Biologics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC